Since DPP4 inhibitors are GLP-1 mimicking rather than blocking DPP4, they disrupt the function of other dipeptide-degrading enzymes, so, probably cause undesired effects8 such as headache, upper respiratory tract infection, and nasopharyngitis. This evidence concerns the gene DPP4 and Recurrent upper respiratory tract infections.